Related Experiment Video
Updated: Jun 17, 2025
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
83.5K
Elafibranor: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|August 7, 2024
Summary
Elafibranor, a PPAR agonist, has gained accelerated US approval for primary biliary cholangitis (PBC). This milestone offers a new treatment option for PBC patients with inadequate response or intolerance to ursodeoxycholic acid.
Area of Science:
- Pharmacology and Gastroenterology
- Drug Development and Regulatory Affairs
Background:
- Primary biliary cholangitis (PBC) is a chronic liver disease requiring novel therapeutic strategies.
- Existing treatments like ursodeoxycholic acid (UDCA) have limitations for some patients.
- Peroxisome proliferator-activated receptor (PPAR) agonists represent a promising class for liver diseases.
Purpose of the Study:
- To summarize the development milestones of elafibranor for PBC treatment.
- To highlight the regulatory pathway leading to elafibranor's approval.
Main Methods:
- Review of elafibranor's development history and clinical trial data.
- Analysis of regulatory submissions and approvals in the USA and EU.
- Focus on elafibranor's mechanism as a PPAR agonist.
Main Results:
- Elafibranor received accelerated approval in the USA on June 10, 2024, for PBC.
- Approval is based on alkaline phosphatase (ALP) reduction in patients with inadequate UDCA response or intolerance.
- Elafibranor has also received a positive opinion in the European Union.
Conclusions:
- Elafibranor represents a significant advancement in PBC treatment.
- This first-in-class PPAR agonist provides a new therapeutic option for a specific PBC patient population.
- The approval marks a key milestone in the drug's journey from development to patient access.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
147
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
147
01:17Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156
01:25Antihypertensive Drugs: Direct Renin Inhibitors
517
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
517
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
720
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
720